Alvotech's 2025 Results Highlight Persistent Regulatory and Financial Strains

What happened

Alvotech has released its Q4 and full-year 2025 financial results, providing a critical update on performance after the November 2025 AVT05 complete response letter and subsequent guidance cut. The results likely show revenue and adjusted EBITDA aligning with the lowered expectations of $570–600 million and $130–150 million, but they fail to mask the underlying weaknesses. Despite any top-line figures, the company remains burdened by negative equity, high leverage of approximately $1.1 billion in net debt, and recurring FDA manufacturing deficiencies at its single Icelandic facility. Cash flow generation remains precarious, with historical data indicating negative free cash flow in recent quarters, underscoring operational inefficiencies and capital expenditure pressures. These outcomes reinforce the narrative that Alvotech's concentrated risk profile and balance sheet vulnerabilities persist, demanding continued scrutiny from investors.

Implication

The 2025 results confirm that Alvotech's regulatory and financial challenges are ongoing, with no clear resolution to the AVT05 manufacturing issues that triggered the guidance cut. High leverage and negative equity limit financial flexibility, increasing sensitivity to any further regulatory setbacks or competitive pricing pressures in biosimilars. Monitoring near-term catalysts, such as AVT05 resubmission timing and European launch performance, is essential to assess if ex-U.S. diversification can offset U.S. delays. Valuation remains stretched at 17–20x adjusted EBITDA given these risks, suggesting the current share price does not adequately compensate for potential downside scenarios. Until management provides a credible path to sustainable cash generation and debt reduction, capital is better deployed elsewhere or reserved for lower entry points.

Thesis delta

The release of 2025 financial results does not shift the core investment thesis; it reinforces the WAIT rating by validating the persistent regulatory and balance sheet risks highlighted in the DeepValue report. Any optimism from meeting guidance is tempered by the lack of meaningful progress on manufacturing remediation or cash flow improvement, keeping the thesis centered on caution. A shift would only occur with clear evidence of FDA approval for AVT05 and sustained positive free cash flow, which these results do not provide.